WO2000056298A2 - Treatment of lyme disease with polysulfated glycosaminoglycan formulations - Google Patents
Treatment of lyme disease with polysulfated glycosaminoglycan formulations Download PDFInfo
- Publication number
- WO2000056298A2 WO2000056298A2 PCT/US2000/006382 US0006382W WO0056298A2 WO 2000056298 A2 WO2000056298 A2 WO 2000056298A2 US 0006382 W US0006382 W US 0006382W WO 0056298 A2 WO0056298 A2 WO 0056298A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- psgag
- gag
- burgdorferi
- antibiotic
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 208000016604 Lyme disease Diseases 0.000 title claims abstract description 43
- 238000011282 treatment Methods 0.000 title claims abstract description 43
- 229940014329 polysulfated glycosaminoglycan Drugs 0.000 title claims description 147
- 238000009472 formulation Methods 0.000 title description 14
- 238000000034 method Methods 0.000 claims abstract description 47
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 44
- 206010003246 arthritis Diseases 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 17
- 208000002166 Erythema Chronicum Migrans Diseases 0.000 claims description 15
- 206010062488 Erythema migrans Diseases 0.000 claims description 15
- 230000003115 biocidal effect Effects 0.000 claims description 15
- 208000015181 infectious disease Diseases 0.000 claims description 15
- 238000002347 injection Methods 0.000 claims description 14
- 239000007924 injection Substances 0.000 claims description 14
- 239000003112 inhibitor Substances 0.000 claims description 12
- 102000004127 Cytokines Human genes 0.000 claims description 10
- 108090000695 Cytokines Proteins 0.000 claims description 10
- 239000003242 anti bacterial agent Substances 0.000 claims description 10
- 210000002808 connective tissue Anatomy 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 241000589969 Borreliella burgdorferi Species 0.000 claims description 8
- 229960003022 amoxicillin Drugs 0.000 claims description 8
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 8
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 8
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 claims description 8
- 229960003081 probenecid Drugs 0.000 claims description 8
- 230000000069 prophylactic effect Effects 0.000 claims description 7
- 108010012236 Chemokines Proteins 0.000 claims description 6
- 102000019034 Chemokines Human genes 0.000 claims description 6
- 229930182555 Penicillin Natural products 0.000 claims description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 6
- 229960004755 ceftriaxone Drugs 0.000 claims description 6
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims description 6
- 229940049954 penicillin Drugs 0.000 claims description 6
- 230000008961 swelling Effects 0.000 claims description 6
- 229940127121 immunoconjugate Drugs 0.000 claims description 5
- 206010023232 Joint swelling Diseases 0.000 claims description 4
- 229960003722 doxycycline Drugs 0.000 claims description 4
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims 3
- 101001086191 Borrelia burgdorferi Outer surface protein A Proteins 0.000 claims 2
- 208000024891 symptom Diseases 0.000 abstract description 10
- 230000002917 arthritic effect Effects 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- 210000000845 cartilage Anatomy 0.000 description 30
- 239000000243 solution Substances 0.000 description 30
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- 102000016611 Proteoglycans Human genes 0.000 description 25
- 108010067787 Proteoglycans Proteins 0.000 description 25
- 102000004190 Enzymes Human genes 0.000 description 22
- 108090000790 Enzymes Proteins 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 229940079593 drug Drugs 0.000 description 19
- 239000003814 drug Substances 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- 210000001503 joint Anatomy 0.000 description 18
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 229920002674 hyaluronan Polymers 0.000 description 17
- 229960003160 hyaluronic acid Drugs 0.000 description 17
- 241000282414 Homo sapiens Species 0.000 description 16
- 239000002244 precipitate Substances 0.000 description 16
- 241000282412 Homo Species 0.000 description 15
- 201000008482 osteoarthritis Diseases 0.000 description 15
- 241000283973 Oryctolagus cuniculus Species 0.000 description 14
- 238000009826 distribution Methods 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 102000008186 Collagen Human genes 0.000 description 12
- 108010035532 Collagen Proteins 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 229920001436 collagen Polymers 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- 210000001179 synovial fluid Anatomy 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 241000589970 Spirochaetales Species 0.000 description 10
- 238000010255 intramuscular injection Methods 0.000 description 10
- 239000007927 intramuscular injection Substances 0.000 description 10
- 210000001188 articular cartilage Anatomy 0.000 description 9
- 230000001925 catabolic effect Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- -1 ibruprofm Chemical compound 0.000 description 9
- 238000007918 intramuscular administration Methods 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 102000055008 Matrilin Proteins Human genes 0.000 description 8
- 108010072582 Matrilin Proteins Proteins 0.000 description 8
- 108010067372 Pancreatic elastase Proteins 0.000 description 8
- 102000016387 Pancreatic elastase Human genes 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- 241000283073 Equus caballus Species 0.000 description 7
- 229940014381 adequan Drugs 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000005067 joint tissue Anatomy 0.000 description 7
- 241000282465 Canis Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 210000001612 chondrocyte Anatomy 0.000 description 6
- 230000003412 degenerative effect Effects 0.000 description 6
- 150000002016 disaccharides Chemical group 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 230000008506 pathogenesis Effects 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 241000283086 Equidae Species 0.000 description 5
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 125000000129 anionic group Chemical group 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 108091007196 stromelysin Proteins 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 208000012659 Joint disease Diseases 0.000 description 4
- 102000005741 Metalloproteases Human genes 0.000 description 4
- 108010006035 Metalloproteases Proteins 0.000 description 4
- 102000035092 Neutral proteases Human genes 0.000 description 4
- 108091005507 Neutral proteases Proteins 0.000 description 4
- 108700006640 OspA Proteins 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 229920002301 cellulose acetate Polymers 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 208000018631 connective tissue disease Diseases 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 230000001066 destructive effect Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- MGXQNMLHMKAXJR-JSCKKFHOSA-N sulfuric acid;(2s,3s,4s,5r)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid Chemical group OS(O)(=O)=O.O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O MGXQNMLHMKAXJR-JSCKKFHOSA-N 0.000 description 4
- 210000002437 synoviocyte Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- IAJILQKETJEXLJ-KLVWXMOXSA-N (2s,3r,4r,5r)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid Chemical compound O=C[C@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-KLVWXMOXSA-N 0.000 description 3
- 206010053555 Arthritis bacterial Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 102000005600 Cathepsins Human genes 0.000 description 3
- 108010084457 Cathepsins Proteins 0.000 description 3
- 229920001287 Chondroitin sulfate Polymers 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- 229920002971 Heparan sulfate Polymers 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 102000001974 Hyaluronidases Human genes 0.000 description 3
- 108050009363 Hyaluronidases Proteins 0.000 description 3
- 208000004575 Infectious Arthritis Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 3
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Chemical group CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 3
- 241000219061 Rheum Species 0.000 description 3
- 208000011312 Vector Borne disease Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000001195 anabolic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940059329 chondroitin sulfate Drugs 0.000 description 3
- 230000003011 chondroprotective effect Effects 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 201000001223 septic arthritis Diseases 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000001258 synovial membrane Anatomy 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- MVVPIAAVGAWJNQ-DOFZRALJSA-N Arachidonoyl dopamine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCC1=CC=C(O)C(O)=C1 MVVPIAAVGAWJNQ-DOFZRALJSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 108090000145 Bacillolysin Proteins 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920000045 Dermatan sulfate Polymers 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 229920000288 Keratan sulfate Polymers 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000031732 Post-Lyme Disease Syndrome Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 238000003916 acid precipitation Methods 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940096529 carboxypolymethylene Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940051593 dermatan sulfate Drugs 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000004124 hock Anatomy 0.000 description 2
- 229940014041 hyaluronate Drugs 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 229950003937 tolonium Drugs 0.000 description 2
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000269858 Anarhichas lupus Species 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 108700016947 Bos taurus structural-GP Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 108010014419 Chemokine CXCL1 Proteins 0.000 description 1
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 1
- 102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 description 1
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229940123922 Disease-modifying osteoarthritis drug Drugs 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 241000238681 Ixodes Species 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- VVBXXVAFSPEIJQ-CVIPOMFBSA-N [(2r)-3-[[(2r)-1-[[(2s,5r,8r,11r,12s,15s,18s,21s)-15-[3-(diaminomethylideneamino)propyl]-21-hydroxy-5-[(4-hydroxyphenyl)methyl]-4,11-dimethyl-2-(2-methylpropyl)-3,6,9,13,16,22-hexaoxo-8-propan-2-yl-10-oxa-1,4,7,14,17-pentazabicyclo[16.3.1]docosan-12-yl]am Chemical compound C([C@@H]1C(=O)N[C@@H](C(=O)O[C@H](C)[C@@H](C(N[C@@H](CCCN=C(N)N)C(=O)N[C@H]2CC[C@H](O)N(C2=O)[C@@H](CC(C)C)C(=O)N1C)=O)NC(=O)[C@H](NC(=O)[C@H](O)COS(O)(=O)=O)CC(C)C)C(C)C)C1=CC=C(O)C=C1 VVBXXVAFSPEIJQ-CVIPOMFBSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000000184 acid digestion Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Polymers CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N ***e Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 230000003366 colagenolytic effect Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 108010074717 glycosaminoglycan receptor Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 150000002344 gold compounds Chemical class 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 239000002117 illicit drug Substances 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000022653 infective arthritis Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates to the treatment of Lyme disease with polysulfated glycosaminoglycan compositions, particularly for the treatment of connective tissue disorders, including arthritis and inflammatory joint conditions associated with Lyme disease.
- the present invention relates to a polysulfated glycosaminoglycan (PSGAG) composition useful for the treatment of Lyme disease associated arthritis and for prophylactic treatment against Lyme disease associated arthritis and joint disorders in patients.
- PSGAG polysulfated glycosaminoglycan
- Lyme disease was first recognized in the United States in 1975, after an outbreak of arthritis near Lyme, Connecticut. Since then reports of Lyme disease have increased dramatically, from 491 cases in 1982 to 12,801 in 1997, and has quickly become the most common vector-transmitted illness in the USA (National Center for Infectious Diseases, Division of Vector-Borne Infectious Diseases: Public Information Guide, ww.cdc.gov/ncidooVdiseases/lyme/lyme.htm, March 3, 1999 and Simon et al, Immunol Today (1991) 12(1):11-16). In endemic areas, its occurrence is extremely common in children (Prose et al,
- Lyme disease is spread by the bite of ticks of the genus Ixodes that are infected with Borerrelia burgdorferi.
- the disease is characterized as a multisystemic disorder, in which the invasive spirochete has a predilection for collagenous tissue which results in one of the major clinical manifestation of the disease; arthritis (Grab et al, FEMS Microbiol Lett (1996) 144(l):39-45).
- Lyme disease is usually treated by antibiotics, however, symptoms may continue to recur, including in about 10% of patients who develop chronic (unremittant for 6 months or more) knee involvement (National Center for Infectious Diseases, Division of Vector-Borne Infectious Diseases: Public Information Guide, www.cdc.gov/ncidod/diseases/fyme/lyme.htm, March 3, 1999 and Merck Manual (Berkow et al, eds) 1992, 16 th edition, ⁇ 1, pages 154-157, Merck Research Laboratories, Merck & Co., Inc., Rahway, N.J.).
- pathogenic microbes are known to cause infections in joints or bones. These forms of reactive arthritis may involve adherence to mammalian host tissues through sulfated carbohydrates, a pathway which has been suggested to be an important trait in microbial pathogenesis.
- pathogens include mycobacteria (Menozzi et al, JExp Med (1996) 184(3):993-101)
- Candida (Dupont et al, J Infect Dis (1985) 152(3):577-591), gonococci (Chen et al, JExp Med (1995) 182(2):511-517), staphylococci (Gallenga et al, Opthalmologica (1998) 212(3):184-187) and Haemophilus influenzae (Noel et al, Infect Immun (1994) 62(9):4028-4033).
- DGI disseminated gonococcal infections
- T cells and macrophages have a direct, effector role in the pathogenesis of Lyme arthritis (Du Chateau et al, Infect Immun (1996) 64(7):2540-2547 and Sigal LH., Ann Rev Immunol (1997) 15:63-92).
- severe destructive arthritis was induced in recipients of macrophages from R. burgdorferi vaccinated animals (Du Chateau et al, Infect Immun (1996) 64(7):2540-2547).
- cytokines and lymphokines e.g., IL-12 inhibitors, CD40 ligand inhibitors, IL-1 inhibitors, Nf-kappa B inhibitors
- IL-12 inhibitors e.g., CD40 ligand inhibitors, IL-1 inhibitors, Nf-kappa B inhibitors
- IL-12 inhibitors e.g., CD40 ligand inhibitors, IL-1 inhibitors, Nf-kappa B inhibitors
- antibiotics such as oral doxycyclin, oral amoxicillin and probenecid.
- aspirin or other non-steroidal anti-inflammatory drugs e.g., idomethacin
- NSATD nonsteroidal anti-inflammatory drugs
- salicylates e.g., aspirin
- gold compounds in addition to NSAIDs
- Penicillimine also can also be given at this stage if gold treatments are unsatisfactory.
- Moderate to severe arthritis requires, as a first treatment, the use of compounds such as hydroxychloroquine and sulfasalazine.
- Polysulfated glycosaminoglycan is a semi-synthetic glycosaminoglycan (GAG) prepared by extracting GAGs from cartilage, for example, bovine tracheal cartilage, and then polysulfating the GAGs.
- GAGs are polysaccharides composed of repeating disaccharide units.
- the GAG present in PSGAG is principally composed of chondroitin sulfate, containing about 3 to 4 sulfate esters per disaccharide unit.
- PSGAG has several biochemical effects on injured or degenerative joints and has been classified as a chondroprotective compound, because PSGAG has been found to be incorporated in the cartilage matrix upon inj ection.
- PSGAG has also been shown to inhibit various catabolic enzymes which degrade glycosaminoglycans competitively, including elastase, stromelysin, metalloproteases, cathepsin Bi, hyaluronidases and collagenases.
- PSGAG has also been demonstrated to indue synthesis of collagen, proteoglycans and hyaluronic acid by chondrocytes and synoviocytes. Further, anti-inflammatory activity has been demonstrated for these molecules.
- GAGs in the treatment of non-Lyme disease related connective tissue disorders also has been disclosed in the medical and patent literature, including methods of treating damage corneal, uterine or cartilage tissues and/or treating rheumatism (see Klundas, U.S. Patent No. 5,036,056 and Akoi et al, U.S. Patent No. 5,470,578).
- these disclosure are limited to repair and/or replacement of GAG loss in the extracellular matrix, and the administration of GAGs would not have been expected to inhibit, for example, the contributory effects of elastases and chondroitinases on connective tissue degeneration as these GAGs themselves would be substrate for such enzymes.
- the literature also describes both the preparation and use of sulfated chondroitin sulfate, including the use of such polysulfated chondroitin for therapy in humans and animals as an antiarthritic treatment (see Wolf U.S. Patent No. 4,534,066).
- PSGAG sulfated chondroitin sulfate
- PSGAG previously was marketed in Europe for the treatment of degenerative joint disorders, and reportedly was most effective as long as there is no extensive full thickness loss of articular cartilage.
- the intramuscular treatment regimen in humans was 50 mg twice weekly for up to 15 injections. That European formulation of PSGAG was taken off the market in 1994 because two deaths occurred in the treated patient group.
- PSGAGs may be safely administered to humans with appropriate care. For example, it is now known that PSGAG should not be administered intra-articularly in the presence of active joint inflammation.
- the ADEQUAN® Canine formulation is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.
- the ADEQUAN® i.m. formulation is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
- the ADEQUAN® CANINE formulation is a formulation of PSGAG for intramuscular administration to dogs. It is sold in a solution of 100 mg/mL in a 5 mL preserved solution.
- ADEQUAN® Canine contains 100 mg of PSGAG, 0.9% v/v benzyl alcohol as a preservative, and water for injection q.s. to 1 mL.
- Sodium hydroxide and/or hydrochloric acid are added when necessary to adjust pH.
- a second product, ADEQUAN® i.m. formulation is a formulation of PSGAG for intramuscular use in horses, which is sold in a solution of 500 mg/5 mL.
- Each 5 milliliters of the ADEQUAN® i.m. formulation contains 500 mg of PSGAG and water for injection q.s.
- Sodium hydroxide and/or hydrochloric acid may be added when necessary to adjust the product's pH.
- PSGAG is chemically similar to the glycosaminoglycans in articular cartilage matrix.
- PSGAG is a potent proteolytic enzyme inhibitor and diminishes or reverses the pathologic processes of traumatic or degenerative joint disease which result in a net loss of cartilage matrix components.
- PSGAG improves joint function by reducing synovial fluid protein levels and increasing synovial fluid hyaluronic acid concentration, for example, in traumatized equine carpal and hock joints.
- PSGAG is characterized as a
- PSGAG disease modifying osteoarthritis drug.
- PSGAG inhibits certain catabolic enzymes that have an increased activity in inflamed joints, and enhances the activity of some anabolic enzymes.
- PSGAG has been shown to significantly inhibit serine proteinases, which have been demonstrated to play a role in the Interleukin-1 mediated degradation of cartilage proteoglycans and collagen.
- PSGAG is reported to be an inhibitor of Prostaglandin E2 (PGE2) synthesis.
- PGE2 has been shown to increase the loss of proteoglycan from cartilage.
- PSGAG also has been reported to inhibit some catabolic enzymes such as elastase, stromelysin, metalloproteases, cathepsin Bl, and hyaluronidases, which degrade collagen, proteoglycans, and hyaluronic acid in degenerative joint disease.
- catabolic enzymes such as elastase, stromelysin, metalloproteases, cathepsin Bl, and hyaluronidases, which degrade collagen, proteoglycans, and hyaluronic acid in degenerative joint disease.
- the anabolic effects of PSGAG include the compound's ability to stimulate the synthesis of protein, collagen, proteoglycans, and hyaluronic acid in various cells and tissues in vitro.
- Cultured human and rabbit chondrocytes have shown increased synthesis of proteoglycan and hyaluronic acid in the presence of PSGAG.
- PSGAGs have shown a specific potentiating effect on hyaluronic acid synthesis by synovial membrane cells in vitro.
- Lyme disease progresses, successful treatment with antibiotics becomes less reliable because of the persistent presence of the spirochete, coupled with an activated immune system. Therefore, what is needed is a more optimal therapy for the various stages of Lyme disease which can: 1) exploit the mechanism of pathogen binding to the infected host's tissue components; 2) repair and replace host ground substance; or 3) modulate immune activation and/or inflammatory responses.
- the present invention relates to a prophylactic or therapeutic treatment for Lyme disease-associated arthritis (LDAA) in a human or mammalian subject, and includes the step of administering an effective amount of a glycosaminoglycan (GAG) composition to a subject in need thereof, particularly a polysulfated GAG (PSGAG).
- GAG glycosaminoglycan
- PSGAG polysulfated GAG
- the composition is administered subsequent to the onset of erythema chronicum migrans (ECM).
- compositions of the present invention may be administered systemically or at the site of swelling, such as by injection at such a site.
- treatment of LDAA involves coadministering an effective amount of a composition comprising a PSGAG and therapeutic amounts of one or more other compounds that also are effective against R. burgdorferi.
- Particularly contemplated other compounds include antibiotic such as tetracycline, doxycycline, penicillin, amoxicillin, probenecid and ceftriaxone or a combination of antibiotics such as amoxicillin and probenecid.
- Other contemplated compounds include antibodies, antibody conjugates, chemokine-inhibitors and cytokine inhibitors.
- Contemplated PSGAG compounds have a molecular weight range between about 3,000 to 15,000 daltons. A preferred range is about 4,000 to 10,000 daltons and a more preferred range is about 5,000 to 8,000 daltons. Numerous additional aspects and advantages of the invention will become apparent to those skilled in the art upon considering the following detailed description of the invention which describes presently preferred embodiments thereof.
- Fig. 1. presents a HP-GPC chromatogram for PSGAG.
- the present invention provides significant improvements in the therapeutic treatment of Lyme disease associated arthritis and associated inflammatory symptoms, particularly involving connective tissue and joint disorders through the use of product formulations which include semisynthetic polysulfated glycosaminoglycans (PSGAGs).
- PSGAGs semisynthetic polysulfated glycosaminoglycans
- Such compositions have been discovered to possess enhanced biochemical activities for such purposes in comparison to naturally occurring glycosaminoglycans (GAGs).
- the present invention provides for a prophylactic treatment for Lyme disease associated arthritis using an injectable form of a PSGAG.
- PSGAG is a biological polymer with a molecular weight range of about 3,000 to 16,000 Daltons.
- the invention relates to the use of this select fraction of PSGAG with a distinct molecular weight distribution and poly-ionic properties.
- Polysulfated glycosaminoglycan (PSGAG) is a poly-anionic mucopolysaccharide that enhances the inhibition of catabolic enzymes while stimulating anabolic pathways for regeneration of damaged cartilage.
- Compositions of PSGAG are useful in the prevention and treatment of inflammatory symptoms associated with degenerative joint diseases. Humans and animals infected with Lyme disease caused by the spirochete, R.
- PSGAG inhibits the attachment of spirochetes, such as R. burgdorferi, to joint (connective) tissues. Since PSGAG enhances the inhibition of neutral protease and inhibits the attachment of R. burgdorferi, to joint (connective) tissues, PSGAG alone or in combination with a suitable antibiotic may be used to treat Lyme disease associated arthritis.
- Treatment comprises systemic administration or direct treatment of specific sites with an effective amount of PSGAG.
- treatment comprises co-administration of PSGAG and other compounds that are therapeutically effective against R. Burgdorferi.
- Preferred compounds that are -Ineffective against R. Burgdorferi include antibiotics, antibodies and chemokine and cytokine inhibitors.
- ECM is a red circular patch that appears usually three days to one month after the bite of an infected tick at the site of the bite. The patch then expands, and sometimes many patches appear that vary in shape. Common sites for such patches are the thigh, groin, trunk and the armpits.
- Co-administered means that two or more different compositions may be administered to a patient simultaneously or sequentially as long as the compositions are administered in a time frame in which the patient derives therapeutic benefit from such two or more compositions.
- Connective tissue means any area of the musculoskeletal system where there is a relatively large portion of extracellular matrix in relation to cells. For example, joints are considered connective tissues.
- LDAA Low Density Associated Arthritis
- LDAA Low Density Associated Arthritis
- these symptoms occur within weeks to months of onset of erythema chronicum mi grans (ECM).
- protection or “therapeutically effective” generally mean that the PSGAG administered is effective to inhibit significantly the attachment of infective microorganisms to their target tissue or cells in an infected host; or that the administered PSGAG is effective to significantly repair and replace host ground substance in the presence of Lyme disease infection; or to significantly reduce the infected host's immunopathological response to the infection.
- PSGAG means the semi-synthetic biological polymer composed of repeating disaccharides units of D-glucuronic acid sulfate and N-acetyl- galactosamine 4, 6 polysulfate. 2. Pharmacology of PSGAG:
- -PSGAG was distributed to all tissues and body fluids investigated -after intra-articular injection, maximum drug concentrations were found a) after 3 hours in the adrenals, thyroids, peritoneal fluid, lungs, eyes, aorta, articular cartilage, synovial fluid and spinal cord b) after 6 hours in kidneys, stomach, testes, adipose tissue, skeletal muscle and brain c) after 24 hours in liver, spleen, bone marrow, salivary glands, thymus, pancreas, skin and heart, -the maximum concentration of drug after intra-articular injection of 1 mg/kg in rabbits (7) in the various organs was given at (all values in dpm/mg or mL): a) kidneys 4782 b) adrenals 439, liver 416, spleen 380, bone marrow 250, thyroids 108, and salivary glands 100 c) thymus 64, pancreas 57, peritoneal fluid 54,
- PSGAG is bound to serum proteins in human blood (6,8,9).
- the drug binds to both albumin and chi- and beta-globulins and the extent of the binding is stated to be 30-40% (8).
- the drug exists in both the bound and free form in the blood stream (8).
- the synovial membrane is not a significant barrier to distribution of PSGAG from the blood stream to the synovial fluid (4,6,8,9,10). Distribution from the synovial fluid to the cartilage takes place by diffusion (11). In the articular cartilage, the drug is deposited into the cartilage matrix (11) and appears to be bound to macromolecules; perhaps to proteoglycans (11) or other non-collagenous proteins (1).
- Metabolism of PSGAG in humans and rabbits includes desulfation and depolymerization (4, 6, 7, 9); metabolites include sulfate, oligosaccharide and monosaccharides. In rabbits, metabolism is reported to take place in the liver, spleen, and bone marrow (7). Metabolism may also occur in the kidneys (13). No metabolism of the drug has been observed in the knee joint of rats (16). It is, however, known that glycosaminoglycans are metabolized by chondrocytes. It has been postulated that PSGAG can be degraded in granulocytes (13) and that extracellular degradation may take place (14).
- PSGAG administered intramuscularly and not protein bound or bound to other tissues is excreted (7). This excretion is primarily via the kidneys, with a very small proportion in the feces. In rabbits, 55.3% of intramuscularly administered PSGAG was excreted in the urine and 1.7 % in the feces within 2 days (4). In humans, 35-40% of a 50 mg intramuscular dose of PSGAG was excreted via the kidneys within 12 hours of administration (6).
- PSGAG has several biochemical effects on injured or degenerative joints. The sum of these effects is called chondroprotection: the inhibition of degradation and effects favorable to repair of articular cartilage (1). Drugs having these effects are classified as chondroprotective.
- PSGAG binds to macromolecules in the extracellular matrix of cartilage; the identity of the binding site is thought to be either a proteoglycan (16) or other noncollagenous protein (1).
- This activity in damaged cartilage with a depleted proteoglycan content has been described as a repair process (17,18,19). It is possible that this binding effect may improve the biochemical properties of damaged cartilage matrix, such as water binding capacity, or may protect damaged matrix components from further enzymatic degradation.
- PSGAG ability of PSGAG to inhibit a broad range of catabolic enzymes has been reported in both in vitro and in vivo test systems. This is significant because enzymatic degradation of collagen, proteoglycans, and hyaluronic acid is a critical element of the pathogenesis of degenerative joint disease (1). Many of the most important of these catabolic enzymes are inhibited by fluid or tissue concentrations of PSGAG as low as about 0.1 to 2 ug/mL in some cases (1,4). The mechanism of enzyme inhibiting varies with the type of enzyme. For many of the glycosidases, which degrade glycosaminoglycans and hyaluronic acid, the inhibition is competitive; the drug acts as a competitive substrate for the enzyme (13).
- Stromelysin is a neutral protease which degrades proteoglycans at low concentrations.
- PSGAG was the only drug tested which significantly inhibited stromelysin at concentrations readily achievable in equine joint tissues (24).
- PSGAG at concentrations of 0.05-0.5 ug/mL inhibited the activity of the enzyme (41).
- PSGAG collagen degrading enzymes
- These enzymes include cathepsin Bi (14,25,26) and elastase (see above).
- PSGAG also inhibits enzymes which degrade hyaluronic acid; the glycoanohydrolases or "hyaluronidases” (13,27,28,29), betaglucuronidase (13,27,28,29,30), and beta-N-acetylglucosaminodases (13,18,28,30).
- hyaluronidases 13,27,28,29
- betaglucuronidase 13,27,28,29,30
- beta-N-acetylglucosaminodases 13,18,28,30.
- PSGAG inhibits enzymes which destroy hyaluronic acid, proteoglycans and collagen.
- Degenerative joint disease is characterized by a net loss of these critical components (1).
- Anabolic Effects in Damaged or Diseased Joint Tissue PSGAG has been reported to stimulate the endogenous synthesis of collagen, proteoglycans and hyaluronic acid by chondrocytes or synoviocytes. The stimulation of proteoglycan and hyaluronate in increased amounts and with higher molecular weight by PSGAG in cultured human chondrocytes has been reported (32). These studies were confirmed in lapine chondrocytes by another investigator (1).
- PSGAG has also been shown to be anti-inflammatory in at least two important pathways.
- PSGAG was shown to inhibit the biosynthesis of the eicosanoid prostaglandin E2 (39).
- This potent inflammatory mediator plays an important role in pain and inflammation in joint disease (1).
- a dose dependent decrease in the release of toxic oxygen radicals from human monrophils by PSGAG has been reported (40).
- Toxic oxygen radicals are implicated in the early breakdown of hyaluronic acid in the synovial fluid of inflamed joints (1).
- Lyme disease may be treated by various therapeutic methods that include the administration of PSGAG. It is contemplated that PSGAG may be coadministered or combined in dosage forms with other anti-Lyme agents including antibiotics, anti-mflammatories, antibodies against R. Burgdorferi epitopes and antibodies against cytokines and chemokines. In a preferred embodiment, PSGAG may be co-administered with the following antibiotics: tetracycline, deoxycycline, penicillin, amoxicillin, ceftriaxone and probenecid. For example, antibodies against R. burgdorferi may be useful in the treatment of this disease, particularly in combination with the administration of PSGAG. Useful antibodies may be generated by standard methods.
- polypeptides, their fragments or other derivatives, or analogs thereof, or cells expressing them can be used as an immunogen to produce antibodies.
- These antibodies can be, for example, polyclonal or monoclonal antibodies, as well as chimeric, single chain, and humanized antibodies, as well as Fab fragments, or the product of an Fab expression library.
- Various procedures known in the art may be used for the production of such antibodies and fragments.
- antibodies may be generated which comprise antibody conjugates (U.S. Patent No. 5,612,016).
- any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler and Milstein, 1975, Nature, 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al, 1983, Immunology Today 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole, et al, 1985, in Monoclonal Antibodies and Cancer Therapy. Alan R. Liss, Inc., pp. 77-96). All of these techniques are incorporated herein by reference. Techniques described in U.S. Patent No. 4,946,778, incorporated herein by reference, for the production of single chain antibodies can be adapted to produce single chain antibodies to immunogenic polypeptide products of this invention.
- antibodies to cytokines or cytokines can be co-administered with PSGAG.
- Cytokines or chemokines can be obtained from any source, most preferably from humans.
- the following chemokines are envisaged: RANTES (U.S. Patent No. 5,451, 660), IP-10 and mig (U.S. Patent No. 5,871, 723), MCP-1 (U.S. Patent No. 5,707,815), gro-alpha and IL-8 (U.S. Patent No. 5,831,032).
- the cytokine IL-12 is preferred.
- antibodies to IL-12 in soluble form, would typically be administered in a single dosage of between 10 mg and 20 mg/kg of body weight.
- 500 mg to 1000 mg can be given P.O.
- 10 mg to 20 mg/kg of body weight can be administered as a single or as a weekly intravenous injection.
- the age, weight and condition of the individual must be considered in determining a final dose.
- 500 mg to 1000 mg can be microencapsulated as described for slow release over a four to eight week period.
- dosages are best optimized by the practicing physician and methods for determining dosages are described for example, in Remington's Pharmaceutical Sciences (24).
- Suitable carriers for oral administration of antibodies to cytokines or lymphokines include one or more substances which may also act as flavoring agents, lubricants, suspending agents, or as protectants.
- Suitable solid carriers include calcium phosphate, calcium carbonate, magnesium stearate, sugars, starch, gelatin, cellulose, carboxypolymethylene, or cyclodextrans.
- Suitable liquid carriers may be water, pharmaceutically accepted oils, or a mixture of both. The liquid can also contain other suitable pharmaceutical additions such as buffers, preservatives, flavoring agents, viscosity or osmo-regulators, stabilizers or suspending agents. Examples of suitable liquid carriers include water with or without various additives, including carboxypolymethylene as a pH-regulated gel.
- the antibodies may be contained in enteric coated capsules that release antibodies into the intestine to avoid gastric breakdown. In a preferred embodiment antibodies are directed to OspA, OspB (U.S.
- Anti-OspA and anti-OspB polypeptide antibodies of this invention may be generated by infection of a mammalian host with B. burgdorferi, or by immunization of a mammalian host with an OspA or OspB polypeptide.
- Such antibodies may be polyclonal or monoclonal, it is preferred that they are monoclonal.
- Methods to produce polyclonal and monoclonal antibodies are well known to those of skill in the art. For a review of such methods, see Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory, ed. E. Harlow and D. Lane (1988), and D. E. Yelton, et al, Ann. Rev. of Biochem., 50, pp. 657-80 (1981).
- OspA and OspB antibodies are combined as pharmaceutical compositions with carriers and adjuvants in their dosage forms.
- the pharmaceutical compositions of OspA and OspB antibodies may be in a variety of conventional depot forms. These include, for example, solid, semi-solid and liquid dosage forms, such as tablets, pills, powders, liquid solutions or suspensions, liposomes, capsules, suppositories, injectable and infusible solutions. The preferred form depends upon the intended mode of administration and prophylactic application.
- Such dosage forms may include pharmaceutically acceptable carriers and adjuvants which are known to those of skill in the art.
- carriers and adjuvants include, for example, RIBI, ISCOM, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances, such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, and polyethylene glycol.
- Adjuvants for topical or gel base forms may be selected from the group consisting of sodium carboxymethylcellulose, polyacrylates, polyoxyethylene-polyoxypropylene-block polymers, polyethylene glycol, and wood wax alcohols.
- Mincing Frozen cartilage is minced. The source of the cartilage is bovine trachea.
- Degreasing The minced cartilage is heated in hot water (80 °C) for twenty minutes. The cartilage's fat is separated from the hot tissue via centrifugation. 2400 kg of frozen cartilage is reduced to 1800 kg after this process. It has lost 25%) of its weight.
- Drying The moist granules of degreased cartilage are dehydrated using hot air (80°C) for 22 hours. The 1700 kg is further reduced to 500 kg. This represents a 60% loss in weight.
- Formaldehyde Treatment 500 kg of intermediate 1 A - 54.65 kg (50.6 liters) is weighted out, added and the mixture then agitated for twenty minutes. The treated cartilage is transferred to PVC drums and stored for 4-9 weeks at room temperature.
- In-Process Specifications The only in-process test is for microbial limits. The limit should be less than 10 micro-organisms per gram with the absence of any harmful species.
- NEUTRALIZATION The extract is transferred to another vessel and the pH is adjusted to 7.2 with hydrochloric acid. The extract is then clarified by filtration.
- a volume of about 5600 liters is evaporated under a vacuum to a volume of 400-480 liters.
- SOLVENT PRECIPITATION Sodium chloride is added to the reduced extract. The pH is adjusted to 7.5 with hydrochloric acid. Four volumes of methanol is added to one volume of extract. The product is allowed to precipitate and settle overnight. The next day the supernate liquid is drawn from the top of the vessel and the precipitated product is suspended in the remaining liquid.
- CENTRIFUGATION The suspension is centrifuged at 400 rpm. The precipitate is collected on polypropylene filter cloth.
- DRYING The precipitate is dried for three hours at 80 °C at atmospheric pressure, then under vacuum for 64 hours.
- GRINDING 25 kg portions are ground in ball mills for 38 hours. The balls are removed and the powder transferred to drums lined with double polyethylene bags.
- ACID SOLVENT PRECIPITATION The hot reaction mixture is added to 260 liters of methanol and mixed for 5 minutes. A precipitate settles and the supernatant is withdrawn. Sodium chloride is added and the precipitate is dissolved in hot water to a volume of 160 liters. 320 liters of methanol is added and the PSGAG precipitates again. The supernatant is again withdrawn.
- Glycosaminoglycan precipitated via the addition of methanol. After settling overnight the supernatant is withdrawn and the precipitate is suspended in the remaining solution. The suspension is centrifuged under a continuous stream of nitrogen. The precipitate is removed and the process repeated three times.
- FILTRATION The dried product is dissolved in a sufficient amount of water. The pH is adjusted to 7.0 and after standing overnight the solution is filtered.
- PRECIPITATION FROM NEUTRAL SOLUTION Four volumes of methanol is added to one volume of filtrate. The pH is maintained at 7. The precipitate is allowed to settle for at least 3 hours. The supernatant is removed and the suspension centrifuged under a continuous stream of nitrogen. The filter cake is rinsed with methanol.
- the filter is dried in the fluid bed drier using hot air.
- the dried precipitate is collected in PVC drums lined with double polyethylene bags.
- Depolymerization Sufficient amounts of Intermediate 3 and sodium chloride are dissolved in water. EDTA and sodium hydroxide are added. The pH is adjusted to 6.05 and the solution is heated to 90 °C. To the hot solution, a hydrogen peroxide solution is stirred in and the temperature maintained for 115 minutes. The solution is then cooled to 25 °C.
- Precipitation/Drying The solution is transferred to another vessel. Sodium chloride is added and the Polysulfated Glycosaminoglycan is again precipitated using methanol. The methanol is recovered and the precipitate collected via filtration. The precipitate is dried as described (IV) 4 above.
- Ion exchange treatment The solution is filtered through a glass column containing a cation exchange resin. The void volume is discarded and a total of 440 liters of filtrate collected.
- Acid precipitation The solution is split and transferred to two separate vessels. Sodium chloride is added to each vessel and the Polysulfated Glycosaminoglycan is again precipitated using methanol. The methanol is recovered and the precipitate collected via filtration. The steps “Filtration”, “Ion Exchange Treatment” and “Acid Precipitation” are repeated two more times.
- Neutral precipitation Sodium chloride is added and the pH is adjusted to 7.5 with sodium hydroxide. A sufficient amount of methanol is added to precipitate the Polysulfated Glycosaminoglycan. The precipitate is recovered via filtration.
- Second filtration The filter cake is dissolved in situ within the closed filter with distilled water. The resulting solution is filtered through a 0.45 micron filter which is integrity tested both before and after use via the bubble point method.
- First membrane filtration Sodium chloride and EDT A are added to the solution. The pH is adjusted to 7.5 with hydrochloric acid. The solution is filtered through an in-line combination of a plate filter and a 0.2 micron cartridge membrane filter. The membrane filter should be integrity tested prior to and after use.
- Polysulfated Glycosaminoglycan is recovered via filtration and washed with methanol. The filtrate is then redissolved in distilled water and more sodium chloride added.
- Second membrane filtration The solution is filtered with a steam- sterilized cartridge membrane filter equipment into a sterile buffer vessel, then combined with 50 liter distilled water washings of the filter housing. The pH is adjusted to 7.5.
- Drying The solution is fed to a spray drier, with an air entrance temperature at 140 and an exit temperature of 85 °C.
- the dried product is collected in a drum lined with double polyethylene bags, then transferred to the quarantine area for sampling and examination by Q.C.
- the yield of the final product is about 64 to 72 kg of white powder.
- Example 2 Characterization of the PSGAG Compounds
- the unique poly-anionic properties of PSGAG is determined by electrophoresis.
- a 70 mm cellulose acetate (CA) membrane, saturated with 0.2 N hydrochloric acid is suspended with contact between the cathode and anode of an electrophoresis chamber.
- a test solution of PSGAG containing about 1 microgram of PSGAG is applied to the cathode end of the strip.
- a current of about 65 mA is applied for 65 minutes.
- the CA membrane is removed from the tank, then stained with a 0.1% toluidine blue solution for 5 minutes.
- the CA membrane is rinsed with a sufficient quantity of water to remove the excess toluidine blue.
- PSGAG appears as only one violet-blue spot at a distance of 3 cm from its starting point.
- the cathode is the negative terminal of the electrophoresis chamber.
- Anionic compounds such as PSGAG, under an applied current will migrate towards the chamber's anode (i.e., its positive terminal).
- the poly-anionic property of PSGAG was compared to hyaluronic acid, chondroitin sulfate A, chondroitin sulfate B (dermatan sulfate), chondroitin sulfate C, heparin sulfate and keratan sulfate using electrophoresis. The results are as follows:
- the molecular weight distribution of PSGAG is determined by High Pressure Gel Permeation Chromatography (HP-GPC).
- HP-GPC High Pressure Gel Permeation Chromatography
- the HP-GPC system uses a high efficiency gel filtration column packed with packed with a bonded diol-coated silica gel with a particle size of 7 microns. The column's molecular weight range is between 100 to 50,000 Daltons.
- a mobile phase consisting of a dilute solution of sodium sulfate (0.05 M) is pumped at a constant flow rate, pressure and temperature.
- Samples of the PSGAG are diluted to 5 mg per mL with the mobile phase and a portion of the resulting solution (10 ⁇ L) is injected into the HP-GPC system.
- a refractive index detector measures the substance's peak response which is proportional to the substance's concentration.
- a computerized GPC software program interprets the data and calculates the relative: weight average molecular weight (M w ), number average molecular weight (M n ) and polydispersity index (M w /M n ) of the sample. These values are based on commercially available molecular weight standards ranging from 1,000 to 47,300 Daltons which are used to calibrate the system immediately prior to sample analysis.
- PSGAG is a semi-synthetic biological polymer composed of repeating disaccharide units of D-glucuronic acid sulfate and N-acetyl-D-galactosamine 4,6 polysulfate. It exhibits a uniform molecular weight distribution curve characterized as follows:
- the preferred dosage form for human use is as a sterile, isotonic solution prepared by dissolving a suitable quantity of PSGAG in water for injection, where the final concentration of PSGAG is between about 50 mg/mL and about 125 mg/mL of PSGAG, preferably between about 75 mg/mL and about 100 mg/mL.
- a sufficient amount of sodium chloride is added to adjust the solution's osmolality to an isotonic range of about 270 to about 330 mOmol/kg.
- suitable antimicrobial preservatives such as benzyl alcohol, methyl paraben and/or propyl paraben may be added at effective concentrations during formulation.
- the bulk solution is sterilized via filtration though a 0.2 micron membrane filter, then aseptically filled into suitable sterile, pyrogen free ampules or vials.
- PSGAG The content of PSGAG in the injection is determined by its hexuronic acid content.
- PSGAG is composed of repeating disaccharide units of D- glucuronic acid sulfate and N-acetyl-D-galactosamine 4,6 polysulfate. Upon acid digestion, the D-glucuronic acid sulfate contained in PSGAG's repeating disaccharide units is hydrolyzed to hexuronic acid. Based on its hexuronic acid content, the injection contains about 90.0 to about 110.0% of its labeled amount of PSGAG.
- the protein content and endotoxin content in PSGAG has been reduced from 0.1 % w/w and 2.5 EU /mg respectively to 0.05% and 0.5 EU/mg.
- Example 4 Treatment of Human Lyme Disease Patients
- the preferred method of treating inflammatory symptoms associated with the chronic, destructive arthritis caused by the spirochete, R. burgdorferi is a suitable injectable formulation of PSGAG administered intra-articularly, intramuscularly, subcutaneously, or by local infiltration at a dose of about 0.5 mg to about 5 mg , preferably about 1 mg to about 4 mg, or more preferably about 2 mg to about 3 mg PSGAG per kilogram body weight twice a week over a seven to eight week period.
- the PSGAG dosage in mg per kilogram body weight administered is sufficient to provide a minimum therapeutic level of about 0.1 ⁇ g/mL of PSGAG throughout its seven to eight week treatment regime.
- PSGAG Since upon administration, PSGAG is distributed to all tissues and body fluids, this minimum therapeutic level of about 0.1 ⁇ g/mL throughout its seven to eight week treatment regime will aid in the inhibition of the attachment ofR. burgdorferi, to joint and other connective tissues. Therefore, PSGAG alone or in combination with a suitable antibiotic may be used to inhibit the attachment of R. burgdorferi, to joint and other connective tissues.
- Greiling H Biochemical investigations of the mode of action of Arteparon. IX Europ Cong Rheumatol Eular Basil 1980 pp 11-18 14. Kruze D, Fehr K, Boni A: Effects of antirheumatic drugs on cathepsin Bl from bovine spleen. Z Rheumatol 35:95-102 1976 15. Enislidis AC: Tissue distribution of tritium labeled glycosaminoglycan polysulfate following intraarticular injection. Med Welt 23: 733-735 1972 16.
- Puhl W The effect of intraarticular injections of Arteparon in osteoarthritis. IX Europ Cong Rheumatol Eular Basil 1980 pp 91-97
- Trnavsky K Effects of Arteparon on the collagenolytic activity of cathepsin Bl. IX Europ Cong Rheumatol Eular Basil 1980 pp 27-29
- Verbruggen G, Veys E M The effect of sulfated glycosaminoglycan on the proteoglycan metabolism of synovial lining cells. Acta Rheumatol Belgica 1 :75-92 1977
- Verbruggen G Veys E M: Proteoglycan metabolism of connective tissue cells. An in vitro technique and its relevance to in vivo conditions. In Degenerative Joints; Test Tubes, Tissues, Models, and Man Amsterdam Excerpta Medica 1982 pp 113-126 33.
- Adam M Krabcova M, Musilova J, Pescova V, Brettschneider I,
- Glade M Polysulfated glycosaminoglycan accelerates net synthesis of collagen and proteoglycans by arthritic equine cartilage tissues and chondrocytes. Am J Vet Res 51:5779-785 1990 36. Nishikawa H, Mon I, Umemoto J,: Influences of sulfated glycosaminoglycans on biosynthesis of hyaluronic acid in rabbit knee synovia. Arch Biochem Biophys 240:146-148 1985
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27199199A | 1999-03-19 | 1999-03-19 | |
US09/271,991 | 1999-03-19 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2000056298A2 true WO2000056298A2 (en) | 2000-09-28 |
WO2000056298A3 WO2000056298A3 (en) | 2001-05-03 |
WO2000056298A9 WO2000056298A9 (en) | 2001-11-29 |
Family
ID=23037944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/006382 WO2000056298A2 (en) | 1999-03-19 | 2000-03-13 | Treatment of lyme disease with polysulfated glycosaminoglycan formulations |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2000056298A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002032407A2 (en) * | 2000-10-19 | 2002-04-25 | Hans-Knöll-Institut für Naturstoff-Forschung e.V. | Use of hyaluronic acid derivatives for the prevention of inflammatory arthritis |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4524066A (en) * | 1981-05-11 | 1985-06-18 | Luitpold-Werk Chemisch-Pharmazeutische Fabrik | Process for the preparation of injectable chondroitin polysulfate |
EP0418827A1 (en) * | 1989-09-19 | 1991-03-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Vaccine against Lyme disease |
US5036056A (en) * | 1987-07-08 | 1991-07-30 | Martin Kludas | Methods for treating damaged corneal, uterine, or cartilage tissue |
EP0441003A2 (en) * | 1989-12-20 | 1991-08-14 | Lawrence Goldman | Ophthalmic medication |
WO1998024477A1 (en) * | 1996-12-06 | 1998-06-11 | Amgen Inc. | Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases |
US5888514A (en) * | 1997-05-23 | 1999-03-30 | Weisman; Bernard | Natural composition for treating bone or joint inflammation |
-
2000
- 2000-03-13 WO PCT/US2000/006382 patent/WO2000056298A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4524066A (en) * | 1981-05-11 | 1985-06-18 | Luitpold-Werk Chemisch-Pharmazeutische Fabrik | Process for the preparation of injectable chondroitin polysulfate |
US5036056A (en) * | 1987-07-08 | 1991-07-30 | Martin Kludas | Methods for treating damaged corneal, uterine, or cartilage tissue |
EP0418827A1 (en) * | 1989-09-19 | 1991-03-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Vaccine against Lyme disease |
EP0441003A2 (en) * | 1989-12-20 | 1991-08-14 | Lawrence Goldman | Ophthalmic medication |
WO1998024477A1 (en) * | 1996-12-06 | 1998-06-11 | Amgen Inc. | Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases |
US5888514A (en) * | 1997-05-23 | 1999-03-30 | Weisman; Bernard | Natural composition for treating bone or joint inflammation |
Non-Patent Citations (5)
Title |
---|
BERKOW R., FLETCHER A.J.: "The Merck Manual of diagnosis and therapy, sixteenth edition." 1992 , MERCK RESEARCH LABORATORIES , RAHWAY, NEW YORK XP002152604 215310 page 154 -page 157 * |
BUDAVARI S., O'NEIL M., SMITH A., HECKELMAN P.: "The Merck Index Eleventh Edition" 1989 , MERCK & CO. , INC. , RAHWAY, N.J. XP002152848 page 735, column 1 * |
KONNO S (REPRINT) ET AL: "REGULATORY EFFECTS OF HEPARIN ON LYMPHOCYTE-PROLIFERATION IN LYME -DISEASE PATIENTS" JOURNAL OF IMMUNOLOGY, (15 APR 1993) VOL. 150, NO. 8, PART 2, PP. A155. ISSN: 0022-1767., XP000961371 NEW YORK MED COLL, DEPT MED, VALHALLA, NY, 10595;NEW YORK MED COLL, DEPT BIOCHEM & MOLEC BIOL, VALHALLA, NY, 10595 * |
LEONG JOHN M ET AL: "Hemagglutination and proteoglycan binding by the Lyme disease spirochete, Borrelia burgdorferi." INFECTION AND IMMUNITY, vol. 63, no. 3, 1995, pages 874-883, XP000957831 ISSN: 0019-9567 cited in the application * |
WADSTROEM TORKEL ET AL: "Glycosaminoglycan-binding microbial proteins in tissue adhesion and invasion: Key events in microbial pathogenicity." JOURNAL OF MEDICAL MICROBIOLOGY, vol. 48, no. 3, March 1999 (1999-03), pages 223-233, XP000957766 ISSN: 0022-2615 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002032407A2 (en) * | 2000-10-19 | 2002-04-25 | Hans-Knöll-Institut für Naturstoff-Forschung e.V. | Use of hyaluronic acid derivatives for the prevention of inflammatory arthritis |
WO2002032407A3 (en) * | 2000-10-19 | 2003-11-20 | Knoell Hans Forschung Ev | Use of hyaluronic acid derivatives for the prevention of inflammatory arthritis |
Also Published As
Publication number | Publication date |
---|---|
WO2000056298A9 (en) | 2001-11-29 |
WO2000056298A3 (en) | 2001-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Berden et al. | Reactive arthritis associated with Campylobacter jejuni enteritis. | |
Ahvonen et al. | Arthritis associated with Yersinia enterocolitica infection | |
Griffin et al. | Guillain-Barré syndrome in northern China: the spectrum of neuropathological changes in clinically defined cases | |
Noack et al. | Glucosamine sulfate in osteoarthritis of the knee | |
Reid et al. | Pathology illustrated E-book | |
Engström-Laurent et al. | Raised serum hyaluronate levels in scleroderma: an effect of growth factor induced activation of connective tissue cells? | |
Puite et al. | Whipple's disease | |
Bull et al. | Enterobacterial common antigen-induced lymphocyte reactivity in inflammatory bowel disease | |
IL194987A (en) | Use of pif peptide in the manufacture of a medicament for modulating the immune system | |
McIlwraith | Management of joint disease in the sport horse | |
Zhang et al. | Shexiang-wulong pills attenuate rheumatoid arthritis by alleviating inflammation in a mouse model of collagen-induced arthritis | |
Pedersen et al. | LongoVital in the treatment of Sjögren’s syndrome | |
Bab et al. | Inflammatory lesions and bone resorption induced in the rat periodontium by lipoteichoic acid of Streptococcus mutans | |
Jacobson et al. | Glossopharyngeal neuralgia with cardiac arrhythmia: a rare but treatable cause of syncope. | |
ES2281265B1 (en) | COMPOSITIONS FOR THE TREATMENT OF ARTROSIS. | |
WO2000056298A2 (en) | Treatment of lyme disease with polysulfated glycosaminoglycan formulations | |
US6476002B1 (en) | Treatment of chronic inflammatory diseases with CM101/GBS toxin | |
Cimmino et al. | Long term treatment of chronic Lyme arthritis with benzathine penicillin. | |
Heydari-Kamjani et al. | Reconsidering the use of minocycline in the preliminary treatment regime of rheumatoid arthritis | |
Ledford | Immunologic aspects of cardiovascular disease | |
Zhang et al. | Clinical applications of haploidentical hematopoietic stem cell transplantation in severe aplastic anemia. | |
Novitch et al. | The emergence of a forgotten entity: Dermatomyositis-like presentation of Lyme disease in rural Wisconsin | |
CN116098886B (en) | Pharmaceutical composition and application thereof | |
Ghosh et al. | Arthritic disease suppression and cartilage protection with glycosaminoglycan polypeptide complexes (Peptacans) derived from the cartilage extracellular matrix: a novel approach to therapy | |
Sorensen et al. | Ten-year course of early-onset Weber-Christian syndrome with recurrent pneumonia: a suggestion for pathogenesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
COP | Corrected version of pamphlet |
Free format text: PAGE 1/1, DRAWINGS, REPLACED BY A NEW PAGE 1/1; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
122 | Ep: pct application non-entry in european phase |